NCT07287202 2025-12-23Safety, Tolerability, and Pharmacokinetics of SVG103 (Paxalisib) in Focal Cortical Dysplasia Type II (FCD-II), Tuberous Sclerosis Complex (TSC) or Hemimegalencephaly (HME)SovargenPhase 1/2 Not yet recruiting15 enrolled